Pricing
Prices are indicative MRP and may vary by pharmacy. Trend compares against the last recorded price.
All price changes →Lucentis
Rx0.5 mg/0.05 ml • Intravitreal Injection
Indications & Uses
Lucentis is indicated for:
Pharmacology
Ranibizumab binds to the receptor binding site of active forms of VEGF-A, and that includes VEGF110, the biologically active, cleaved form of the molecule. In models of ocular angiogenesis and vascular occlusion, VEGF-A has been shown to cause neovascularization and leakage. It is thought to contribute to the pathophysiology of neovascular AMD, mCNV, DR, DME and macular edema following RVO.
When ranibizumab attaches to VEGF-A, VEGF-A can no longer interact with its receptors, VEGFR1 and VEGFR2, on the surface of endothelial cells. This reduces endothelial cell proliferation, vascular leakage and the formation of new blood vessels.
Dosage Reference
Reference Information Only
Dosages shown are general references from official sources. Always consult your doctor or pharmacist for personalized dosing.
Adults:
Neovascular (Wet) Age-Related Macular Degeneration (AMD)
The recommended dose of Ranibizumab is 0.5 mg (0.05 mL of 10 mg/mL solution), given as an intravitreal injection once a month (approximately 28 days). Patients may also be treated with 3 monthly doses followed by less frequent dosing with regular assessment, although this is not as effective. In the 9 months after the three initial monthly doses, less frequent dosing with 4 to 5 doses on average is expected to maintain visual acuity, while monthly dosing may be expected to give an additional average gain of 1 to 2 letters. Patients should be assessed regularly.
Another option, again not as effective, is one dose every 3 months after 4 monthly doses. Compared with continued monthly dosing, dosing every 3 months over the next 9 months will lead to an approximate 5-letter (1-line) loss of visual acuity benefit, on average. Patients should be assessed regularly.
Macular Edema Following Retinal Vein Occlusion (RVO)
Ranibizumab 0.5 mg (0.05 mL of 10 mg/mL solution) is recommended as an intravitreal injection once a month (approximately 28 days). In Studies RVO-1 and RVO-2, patients received monthly injections of Ranibizumab for 6 months. Re-treatment was guided by optical coherence tomography and visual acuity criteria. Even so, patients who were not treated at Month 6 lost visual acuity on average at Month 7, while patients who were treated at Month 6 did not. Patients should be treated monthly.
Diabetic Macular Edema (DME) and Diabetic Retinopathy (DR)
The recommended dose is Ranibizumab 0.3 mg (0.05 mL of 6 mg/mL solution), given as an intravitreal injection once a month (approximately 28 days).
Myopic Choroidal Neovascularization (mCNV)
Ranibizumab 0.5 mg (0.05 mL of 10 mg/mL Ranibizumab solution) is recommended as an intravitreal injection once a month (approximately 28 days) for up to 3 months at the start. Patients may be retreated if needed.
Side Effects
The side effects of Ranibizumab include endophthalmitis and retinal detachments, increases in intraocular pressure, and thromboembolic events. Fatal events have also been reported in patients who had DME and DR at baseline.
Cautions & Contraindications
Warnings & Precautions
Endophthalmitis and Retinal Detachments Intravitreal injections, including those with Ranibizumab, have been linked to endophthalmitis and retinal detachments. Always use a proper aseptic injection technique when giving Ranibizumab. The patient should also be monitored after the injection, so that any infection can be treated early. Increases in Intraocular Pressure Intraocular pressure has risen both before and after injection (at 60 minutes) in people being treated with Ranibizumab. Check the pressure before and after the intravitreal injection and manage it appropriately. Thromboembolic Events Although the rate of arterial thromboembolic events (ATEs) in the Ranibizumab clinical trials was low, there is still a potential risk of ATEs after intravitreal use of VEGF inhibitors. Arterial thromboembolic events are defined as nonfatal stroke, nonfatal myocardial infarction, or vascular death (including deaths of unknown cause).
Contraindications
Ranibizumab must not be used in people who have an infection in or around the eye (an ocular or periocular infection). It must also not be given to anyone with known hypersensitivity to ranibizumab or to any of the excipients in Ranibizumab. A hypersensitivity reaction can show up as severe inflammation inside the eye.
Pregnancy & Breastfeeding
No adequate and well-controlled studies of Ranibizumab have been done in pregnant women. There are also no data on whether ranibizumab passes into human milk, what effect it has on a breastfed infant, or whether it changes milk production or excretion.
⚠️ Talk to your doctor before taking any medicine during pregnancy or while breastfeeding.
Storage
Keep Ranibizumab between 2 and 8°C, and protect it from light. Keep it out of reach of children.
Common questions about Lucentis 0.5 mg/0.05 ml
What is Lucentis 0.5 mg/0.05 ml Intravitreal Injection?
Lucentis 0.5 mg/0.05 ml Intravitreal Injection is a medicine that contains Ranibizumab. It is made by Nevian Lifescience PLC. It belongs to the Drugs for Age-Related Macular Degeneration (AMD) group of medicines.
What is Lucentis used for?
Lucentis is used for: Edema.
What are the side effects of Lucentis?
The side effects of Ranibizumab include endophthalmitis and retinal detachments, increases in intraocular pressure, and thromboembolic events. Fatal events have also been reported in patients who had DME and DR at baseline.
Can I take Lucentis during pregnancy or while breastfeeding?
No adequate and well-controlled studies of Ranibizumab have been done in pregnant women. There are also no data on whether ranibizumab passes into human milk, what effect it has on a breastfed infant, or whether it changes milk production or excretion. Talk to your doctor before taking any medicine during pregnancy or while breastfeeding.
How should I store Lucentis?
Keep Ranibizumab between 2 and 8°C, and protect it from light. Keep it out of reach of children.
Do I need a prescription for Lucentis?
Lucentis is a prescription (Rx) medicine. Take it as your doctor advises.